NCT01349036 - A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 3, 2011

Primary Completion Date

November 5, 2013

Study Completion Date

November 5, 2013

Conditions

Recurrent Glioblastoma

Interventions

DRUG

PLX3397

Capsules administered once or twice daily, continuous dosing

Trial Locations (6)

Memorial Sloan Kettering Cancer Center, New York

University of Texas, MD Anderson Cancer Center, Houston

Huntsman Cancer Institute University of Utah, Salt Lake City

University California, Los Angeles, Los Angeles

University California, San Francisco, San Francisco

Dana Faber Cancer Institute, Boston